NYSE:AGN - Allergan Stock Price, News & Analysis

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan declared a quarterly dividend on Friday, July 19th. Shareholders of record on Tuesday, August 13th will be given a dividend of $0.74 per share on Friday, September 13th. This represents a $2.96 dividend on an annualized basis and a yield of 1.78%. The ex-dividend date of this dividend is Monday, August 12th. View Allergan's Dividend History.

Allergan announced that its board has approved a stock buyback plan on Tuesday, January 29th 2019, which authorizes the company to repurchase $2,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 4.1% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's leadership believes its stock is undervalued.

Allergan plc (NYSE:AGN) announced its quarterly earnings results on Tuesday, August, 6th. The company reported $4.38 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $4.34 by $0.04. The company had revenue of $4.09 billion for the quarter, compared to the consensus estimate of $3.93 billion. Allergan had a positive return on equity of 8.73% and a negative net margin of 54.25%. Allergan's revenue for the quarter was down .8% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.42 EPS. View Allergan's Earnings History.

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for Allergan.

Allergan updated its FY19 earnings guidance on Tuesday, August, 6th. The company provided earnings per share guidance of >$16.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.74. The company issued revenue guidance of 15.4-15.6 billion, compared to the consensus revenue estimate of $15.32 billion.

21 brokerages have issued 1-year price targets for Allergan's shares. Their predictions range from $144.95 to $255.00. On average, they expect Allergan's stock price to reach $178.7515 in the next twelve months. This suggests a possible upside of 7.6% from the stock's current price. View Analyst Price Targets for Allergan.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 15 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Allergan.

News articles about AGN stock have been trending negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Allergan earned a news sentiment score of -2.9 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Allergan.

Allergan saw a increase in short interest in August. As of August 31st, there was short interest totalling 7,261,500 shares, an increase of 22.5% from the July 31st total of 5,926,900 shares. Based on an average trading volume of 4,930,000 shares, the short-interest ratio is currently 1.5 days. Approximately 2.2% of the shares of the company are short sold. View Allergan's Current Options Chain.

Some companies that are related to Allergan include Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Sanofi (SNY), Eli Lilly And Co (LLY), AbbVie (ABBV), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Bayer (BAYRY), Celgene (CELG) and Zoetis (ZTS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

Allergan's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.36%), BlackRock Inc. (6.04%), BlackRock Inc. (6.04%), Longview Partners Guernsey LTD (2.13%), Northern Trust Corp (1.21%) and Baupost Group LLC MA (1.12%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh and William Meury. View Institutional Ownership Trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Janus Henderson Group PLC, King Street Capital Management L.P., Iridian Asset Management LLC CT, Baupost Group LLC MA, BlackRock Inc., BlackRock Inc. and Invesco Ltd.. View Insider Buying and Selling for Allergan.

AGN stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Magnetar Financial LLC, OZ Management LP, Paulson & CO. Inc., Longview Partners Guernsey LTD, Alpine Associates Management Inc., TIG Advisors LLC and TIG Advisors LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $166.10.

Allergan has a market capitalization of $54.49 billion and generates $15.79 billion in revenue each year. The company earns $-5,096,400,000.00 in net income (profit) each year or $16.69 on an earnings per share basis. Allergan employs 16,900 workers across the globe.View Additional Information About Allergan.

The official website for Allergan is http://www.allergan.com/.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]